Kanser Tedavisinde Tanşinon-Iıa İle Emt’nin Hedeflenmesi
Özet
Kanser, dünyada mortalite ve morbiditenin başlıca nedenlerinden birisidir. Kanser ve metastaz süreçlerinin anlaşılması, yeni tedavi stratejilerinin geliştirilmesi açısından büyük önem taşımaktadır. Epitelyal-mezenkimal geçiş (EMT), kanser hücrelerinin invazyon, metastaz ve kemoterapi direnci gelişiminde kritik rol oynar. Son yıllarda doğal kaynaklı bileşiklerin kanser tedavisindeki etkileri araştırılmaktadır. Salvia miltiorrhiza bitkisinden elde edilen Tanşinon-IIA, lipofilik bir diterpen kinon yapısına sahiptir ve antioksidan, antiinflamatuvar, kardiyoprotektif ve antikanser etkileri literatürde bildirilmiştir. Yapılan çalışmalar, Tanşinon-IIA’nın çeşitli kanser türlerinde hücre proliferasyonunu baskıladığını, apoptozu indüklediğini, anjiyogenez, invazyon ve metastazı azalttığını göstermektedir. Özellikle EMT sürecini hedefleyerek E-kaderin ekspresyonunu artırdığı; N-kaderin, vimentin, Snail ve Slug gibi mezenkimal belirteçlerin ekspresyonunu azalttığı bildirilmiştir. Ayrıca STAT3-CCL2 ve PI3K/Akt/ERK gibi sinyal yolaklarını düzenleyerek EMT’yi baskıladığı ve böylece tümör ilerlemesini, metastazı ve ilaç direncini azalttığı ortaya konmuştur. Bununla birlikte, biyoyararlanımının düşük olması ve potansiyel toksisite riskleri klinik kullanımını konusunda sınırlamalara yol açmaktadır. Bu kitap bölümünde doğal bir fitokimyasal ajanlardan biri olan Tanşinon-IIA’nın, EMT’yi hedeflemesi yoluyla kanser tedavi süreçlerine ve klinik uygulamalara yönelik etkisinin araştırılmasının önemi vurgulanmıştır.
Cancer is one of the leading causes of mortality and morbidity worldwide. Understanding the processes of cancer development and metastasis is important for the development of new therapeutic strategies. Epithelial-mesenchymal transition (EMT) plays a critical role in cancer cell invasion, metastasis, and the development of chemoresistance. In recent years, the effects of naturally derived compounds in cancer therapy have attracted considerable research interest. Tanshinone-IIA, obtained from the plant Salvia miltiorrhiza, is a lipophilic diterpene quinone compound. Its antioxidant, anti-inflammatory, cardioprotective, and anticancer properties have been reported in the literature. Studies have demonstrated that Tanshinone-IIA suppresses cell proliferation, induces apoptosis, and reduces angiogenesis, invasion, and metastasis in various types of cancer. It has been reported to target the EMT process by increasing E-cadherin expression while decreasing the expression of mesenchymal markers such as N-cadherin, vimentin, Snail, and Slug. Furthermore, Tanshinone-IIA was shown to inhibit EMT by regulation of signaling pathways including STAT3-CCL2 and PI3K/Akt/ERK, thereby reducing tumor progression, metastasis, and drug resistance. However, its low bioavailability and potential toxicity risks pose limitations to its clinical application. This book chapter emphasizes the importance of Tanshinone-IIA, a natural phytochemical agent, on cancer treatment and clinical applications through its ability to target EMT.
Referanslar
Dias, D.A., Urban, S., & Roessner, U.A. (2012). Historical Overview of Natural Products in Drug Discovery. Metabolites, 16;2(2):303–36. https://doi.org/10.3390/metabo2020303.
Chihomvu, P., Ganesan, A., & Gibbons, S. (2024). Phytochemicals in Drug Discovery—A Confluence of Tradition and Innovation. International Journal of Molecular Sciences, 13;25(16):8792. https://doi.org/10.3390/ijms25168792.
Kumar, A., P, N., & Kumar, M. (2023). Major Phytochemicals: Recent Advances in Health Benefits and Extraction Method. Molecules, 16;28(2):887. https://doi.org/10.3390/molecules28020887.
Campos-Vega, R., Oomah, BD. (2013). Chemistry and classification of phytochemicals. Handbook of plant food phytochemicals. Tiwari, B.K., Brunton, N.P., & Brennan, C.s. (Eds.) (pp.5–48). https://doi.org/10.1002/9781118464717.ch2.
Zhong, W., Qian, K., & Xiong, J. (2016). Curcumin alleviates lipopolysaccharide induced sepsis and liver failure by suppression of oxidative stress-related inflammation via PI3K/AKT and NF-κB related signaling. Biomedicine & Pharmacotherapy, 83:302–13. https://doi.org/10.1016/j.biopha.2016.06.036.
Peng, S.J., Li, J., & Zhou, Y. (2017). In vitro effects and mechanisms of lycopene in MCF-7 human breast cancer cells. Genetics and Molecular Research, 16(2). https://doi.org/10.4238/gmr16029434.
Xia, X., Yan, J., & Shen, Y. (2011). Berberine Improves Glucose Metabolism in Diabetic Rats by Inhibition of Hepatic Gluconeogenesis. PLoS One, 6(2):e16556. https://doi.org/10.1371/journal.pone.0016556.
Domitrović, R., Cvijanović, O., & Pernjak-Pugel, E. (2013). Berberine exerts nephroprotective effect against cisplatin-induced kidney damage through inhibition of oxidative/nitrosative stress, inflammation, autophagy and apoptosis. Food and Chemical Toxicology, 62:397–406. https://doi.org/10.1016/j.fct.2013.09.003.
Muñoz, J.E., Rossi, D.C.P., & Jabes, D.L. (2020). In Vitro and In Vivo Inhibitory Activity of Limonene against Different Isolates of Candida spp. Journal of Fungi, 22;6(3):183. https://doi.org/10.3390/jof6030183.
Paul, J.K., Azmal, M., & Haque, A.S.N.B. (20204). Phytochemical-mediated modulation of signaling pathways: A promising avenue for drug discovery. Advances in Redox Research, 13:100113. https://doi.org/10.1016/j.arres.2024.100113.
WHO (2025). Cancer. (8 Ekim 2025 tarihinde https://www.who.int/health-topics/cancer#tab=tab_1 adresinden ulaşılmıştır).
IARC (2025). Cancer Tomorrow. (8 Ekim 2025 tarihinde https://gco.iarc.who.int/tomorrow/en/dataviz/isotype adresinden ulaşılmıştır).
IARC (2025). Absolute numbers, Incidence, Both sexes, in 2022. (8 Ekim 2025 tarihinde https://gco.iarc.fr/today/en/dataviz/pie?mode=population&group_populations=0 adresinden ulaşılmıştır).
IARC (2025). Absolute numbers, Mortality, Both sexes, in 2022. (8 Ekim 2025 tarihinde https://gco.iarc.fr/today/en/dataviz/pie?mode=population&group_populations=0&types=1 adresinden ulaşılmıştır).
Syed, V. (2016). TGF‐β Signaling in Cancer. Journal of Cellular Biochemistry, 117(6):1279–87. https://doi.org/10.1002/jcb.25496.
Ghosh, C., & Hu, J. (2024). Importance of targeting various cell signaling pathways in solid cancers. International review of cell and molecular biology, 385,101–155. https://doi.org/10.1016/bs.ircmb.2024.02.002.
Das, V., Bhattacharya, S., & Chikkaputtaiah, C. (2019). The basics of epithelial–mesenchymal transition (EMT): A study from a structure, dynamics, and functional perspective. Journal of Cell Physiology, 234(9):14535–55. https://doi.org/10.1002/jcp.28160.
Kim, D.H., Xing, T., & Yang, Z. (2017). Epithelial Mesenchymal Transition in Embryonic Development, Tissue Repair and Cancer: A Comprehensive Overview. Journal of clinical medicine, 7(1):1. https://doi.org/10.3390/jcm7010001.
Acloque, H., Adams, M.S., & Fishwick, K. (2009). Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. Journal of Clinical Investigation, 119(6):1438–49. https://doi.org/10.1172/JCI38019.
Thiery, J.P., Acloque, H., & Huang, R.Y.J. (2009). Epithelial-Mesenchymal Transitions in Development and Disease. Cell. 139(5):871–90. https://doi.org/10.1016/j.cell.2009.11.007.
Pastushenko, I., & Blanpain, C. (2019). EMT Transition States during Tumor Progression and Metastasis. Trends in Cell Biology, 29(3):212–26. https://doi.org/10.1016/j.tcb.2018.12.001.
Craene, B., & Berx, G. (2013). Regulatory networks defining EMT during cancer initiation and progression. Nature Reviews, Cancer. 13(2):97–110. https://doi.org/10.1038/nrc3447.
Buyuk, B., Jin, S., & Ye, K. (2021). Epithelial-to-Mesenchymal Transition Signaling Pathways Responsible for Breast Cancer Metastasis. Cellular and Molecular Bioengineering, 15(1):1–13. https://doi.org/10.1007/s12195-021-00694-9.
Wang, H., Guo, S., & Kim, S.J. (2021). Cisplatin prevents breast cancer metastasis through blocking early EMT and retards cancer growth together with paclitaxel. Theranostics, 11(5):2442–59. https://doi.org/10.7150/thno.46460.
Liao, Y., Gui, Y., & Li, Q. (2023). The signaling pathways and targets of natural products from traditional Chinese medicine treating gastric cancer provide new candidate therapeutic strategies. Biochimica et Biophysica Acta. Reviews on Cancer, 1878(6):188998. https://doi.org/10.1016/j.bbcan.2023.188998.
Ma, Y., Yuan, L., & Wu, B. (2012). Genome-wide identification and characterization of novel genes involved in terpenoid biosynthesis in Salvia miltiorrhiza. Journal of Experimental Botany, 63(7):2809–23. https://doi.org/10.1093/jxb/err466.
Du, G., Song, J., & Du. L. (2020). Chemical and pharmacological research on the polyphenol acids isolated from Danshen: A review of salvianolic acids. Du, G. (Ed.), Advances in Pharmacology, p. 1–41. https://doi.org/10.1016/bs.apha.2019.12.004.
Zhou, L., Zuo, Z., & Chow, M.S.S. (2005). Danshen: An Overview of Its Chemistry, Pharmacology, Pharmacokinetics, and Clinical Use. The Journal of Clinical Pharmacology. 45(12):1345–59. https://doi.org/10.1177/0091270005282630.
Shao, S., Lv, B., & Wang, M. (2025). Biosynthesis and regulatory mechanism of tanshinones and phenolic acids in Salvia miltiorrhiza. The Plant Journal, 123(2). https://doi.org/10.1111/tpj.70358.
Yuen, C.W., Murugaiyah, V., & Najimudin, N. (2021). Danshen (Salvia miltiorrhiza) water extract shows potential neuroprotective effects in Caenorhabditis elegans. Journal of Ethnopharmacology, 266:113418. https://doi.org/10.1016/j.jep.2020.113418.
Jiang, X li., Li, J kui., & Zhu, P li. (2025). Danshen (Salvia miltiorrhiza) extract suppresses the growth of melanoma cells and induces autophagy by inhibiting the STAT3 pathway. Journal of Ethnopharmacology, 351:120086. https://doi.org/10.1016/j.jep.2025.120086.
PubChem (2025). Tanshinone IIa. (23 Ekim 2025 tarihinde https://pubchem.ncbi.nlm.nih.gov/compound/Tanshinone-IIA#section=2D-Structure adresinden ulaşılmıştır).
Wu, T.W., Zeng, L.H., & Fung, K.P. (1993). Effect of sodium tanshinone IIA sulfonate in the rabbit myocardium and on human cardiomyocytes and vascular endothelial cells. Biochemical Pharmacology, 46(12):2327–32. https://doi.org/10.1016/0006-2952(93)90624-6.
Niu, X.L., Ichimori, K., & Yang, X. (2000). Tanshinone II-A inhibits low density lipoprotein oxidation in vitro. Free Radical Research, 33(3):305–12. https://doi.org/10.1080/10715760000301471.
Chiu, S.C., Huang, S.Y., & Chen, S.P. (203). Tanshinone IIA inhibits human prostate cancer cells growth by induction of endoplasmic reticulum stress in vitro and in vivo. Prostate Cancer and Prostatic Diseases, 16(4):315–22. https://doi.org/10.1038/pcan.2013.38.
Xu, Z., Chen, L., & Xiao, Z. (2018). Potentiation of the anticancer effect of doxorubicinin drug-resistant gastric cancer cells by tanshinone IIA. Phytomedicine, 51:58–67. https://doi.org/10.1016/j.phymed.2018.05.012.
Jiang, Y., Bi, Y., & Zhou, L. (2024). Tanshinone IIA inhibits proliferation and migration by downregulation of the PI3K/Akt pathway in small cell lung cancer cells. BMC Complementary Medicine and Therapies, 24(1):68. https://doi.org/10.1186/s12906-024-04363-y.
Ding, B., Lin, C., & Liu, Q. (2020). Tanshinone IIA attenuates neuroinflammation via inhibiting RAGE/NF-κB signaling pathway in vivo and in vitro. Journal of Neuroinflammation, 17(1):302. https://doi.org/10.1186/s12974-020-01981-4.
Xie, J., Liu, JH., & Liu, H. (2016). Tanshinone IIA combined with adriamycin inhibited malignant biological behaviors of NSCLC A549 cell line in a synergistic way. BMC Cancer, 16(1):899. https://doi.org/10.1186/s12885-016-2921-x.
Di Cesare Mannelli, L., Piccolo, M., & Maione, F. (2018). Tanshinones from Salvia miltiorrhiza Bunge revert chemotherapy-induced neuropathic pain and reduce glioblastoma cells malignancy. Biomedicine & Pharmacotherapy, 105:1042–9. https://doi.org/10.1016/j.biopha.2018.06.047.
Wang, J.F., Feng, J.G., & Han, J. (2014). The Molecular Mechanisms of Tanshinone IIA on the Apoptosis and Arrest of Human Esophageal Carcinoma Cells. BioMed Research International, 2014:1–9. https://doi.org/10.1155/2014/582730.
Liu, J., Zhang, C., & Liu, S. (2023). Tanshinone IIA promotes apoptosis by downregulating BCL2 and upregulating TP53 in triple-negative breast cancer. Naunyn-Schmiedeberg’s Archives of Pharmacology, 396(2):365–74. https://doi.org/10.1007/s00210-022-02316-1.
Yuxian, X., Feng, T., & Ren, L. (2009). Tanshinone II-A Inhibits Invasion and Metastasis of Human Hepatocellular Carcinoma Cells in Vitro and in Vivo. Tumori, 95(6):789–95. https://doi.org/10.1177/030089160909500623.
Lee, H.P., Liu, Y.C., & Chen, P.C. (2017). Tanshinone IIA inhibits angiogenesis in human endothelial progenitor cells in vitro and in vivo. Oncotarget, 8(65):109217–27. https://doi.org/10.18632/oncotarget.22649.
Song, Q., Yang, L., & Han, Z. (2020). Tanshinone IIA Inhibits Epithelial-to-Mesenchymal Transition Through Hindering β-Arrestin1 Mediated β-Catenin Signaling Pathway in Colorectal Cancer. Frontiers in Pharmacology, 11, 586616. https://doi.org/10.3389/fphar.2020.586616.
Huang, S.Y., Chang, S.F., & Liao, K.F. Tanshinone IIA Inhibits Epithelial-Mesenchymal Transition in Bladder Cancer Cells via Modulation of STAT3-CCL2 Signaling. International journal of molecular sciences, 18(8):1616. https://doi.org/10.3390/ijms18081616.
Zhang, L., Lin, W., & Chen, X. (2019). Tanshinone IIA reverses EGF and TGF β1 mediated epithelial mesenchymal transition in HepG2 cells via the PI3K/Akt/ERK signaling pathway. Oncology Letters, 18(6):6554-6562. https://doi.org/10.3892/ol.2019.11032.
Fu, P., Du, F., & Chen, W. (2014). Tanshinone IIA blocks epithelial-mesenchymal transition through HIF-1α downregulation, reversing hypoxia-induced chemotherapy resistance in breast cancer cell lines. Oncology Reports, 31(6):2561–8. https://doi.org/10.3892/or.2014.3140.
Qin, J., Shi, H., & Xu, Y. (2018). Tanshinone IIA inhibits cervix carcinoma stem cells migration and invasion via inhibiting YAP transcriptional activity. Biomedicine & Pharmacotherapy, 105:758–https://doi.org/10.1016/j.biopha.2018.06.028.
Wang, T., Wang, C., & Wu, Q. (2017). Evaluation of Tanshinone IIA Developmental Toxicity in Zebrafish Embryos. Molecules, 22(4):660. https://doi.org/10.3390/molecules22040660.
Hu, W., Si, Y., & Wen, X. (2025). Pharmacological Effects and Mechanisms of Tanshinone IIA in Bone Injury Repair. Pharmaceuticals, 18(9):1338. https://doi.org/10.3390/ph18091338.
